<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Mifepristone</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00834</strong>&#160; (APRD00432)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome [PubChem]. The two marketed forms of mifepristone are Mifeprex&#174; (mifepristone 200mg) and Korlym&#8482; (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00834/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00834/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00834.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00834.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00834.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00834.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00834.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00834">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Mifepriston</td><td>German</td><td>INN</td></tr><tr><td>Mifepristona</td><td>Spanish</td><td>INN</td></tr><tr><td>Mif&#233;pristone</td><td>French</td><td>INN</td></tr><tr><td>Mifepristonum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Corlux</td><td>Corcept Therapeutics Incorporated</td></tr><tr><td>Korlym</td><td>Corcept Therapeutics</td></tr><tr><td>Mefipil</td><td>Abbott</td></tr><tr><td>Mifegyne</td><td>Exelgyn Laboratories</td></tr><tr><td>Mifeprex</td><td>Danco Laboratories</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hormone-antagonists">Hormone Antagonists</a></li>
<li><a href="/mesh/contraceptives-oral-synthetic">Contraceptives, Oral, Synthetic</a></li>
<li><a href="/mesh/abortifacient-agents-steroidal">Abortifacient Agents, Steroidal</a></li>
<li><a href="/mesh/contraceptives-postcoital-synthetic">Contraceptives, Postcoital, Synthetic</a></li>
<li><a href="/mesh/luteolytic-agents">Luteolytic Agents</a></li>
<li><a href="/mesh/menstruation-inducing-agents">Menstruation-Inducing Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>84371-65-3</td></tr><tr><th>Weight</th><td>Average: 429.5937<br>Monoisotopic: 429.266779369</td></tr><tr><th>Chemical Formula</th><td>C<sub>29</sub>H<sub>35</sub>NO<sub>2</sub></td></tr><tr><th>InChI Key</th><td>VKHAHZOOUSRJNA-GCNJZUOMSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-5-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Steroids and Steroid Derivatives</td></tr><tr><th>Subclass</th><td>Ketosteroids</td></tr><tr><th>Direct parent</th><td>Ketosteroids</td></tr><tr><th>Alternative parents</th><td>Hydroxysteroids; Ynones; Benzene and Substituted Derivatives; Tertiary Alcohols; Tertiary Amines; Cyclic Alcohols and Derivatives; Polyamines</td></tr><tr><th>Substituents</th><td>ynone; benzene; cyclic alcohol; tertiary alcohol; tertiary amine; ketone; polyamine; organonitrogen compound; amine; alcohol; carbonyl group</td></tr><tr><th>Classification description</th><td>This compound belongs to the ketosteroids. These are steroid derivatives comprising a ketone group attached to steroid skeleton.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.</td></tr><tr><th>Pharmacodynamics</th><td>Mifepristone is a synthetic steroid with antiprogestational effects indicated for the medical termination of intrauterine pregnancy through 49 days' pregnancy. Doses of 1 mg/kg or greater of mifepristone have been shown to antagonize the endometrial and myometrial effects of progesterone in women. During pregnancy, the compound sensitizes the myometrium to the contraction-inducing activity of prostaglandins. Mifepristone also exhibits antiglucocorticoid and weak antiandrogenic activity. The activity of the glucocorticoid dexamethasone in rats was inhibited following doses of 10 to 25 mg/kg of mifepristone. Doses of 4.5 mg/kg or greater in human beings resulted in a compensatory elevation of adrenocorticotropic hormone (ACTH) and cortisol.</td></tr><tr><th>Mechanism of action</th><td>The anti-progestational activity of mifepristone results from competitive interaction with progesterone at progesterone-receptor sites. Based on studies with various oral doses in several animal species (mouse, rat, rabbit and monkey), the compound inhibits the activity of endogenous or exogenous progesterone. The termination of pregnancy results.

In the treatment of Cushing's syndrome, Mifepristone blocks the binding of cortisol to its receptor. It does not decrease cortisol production but reduces the effects of excess cortisol, such as high blood sugar levels.</td></tr><tr><th>Absorption</th><td>The absolute bioavailability of a 20 mg oral dose is 69%</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>98% (bound to plasma proteins, albumin and a 1-acid glycoprotein)</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Hepatic, by Cytochrome P450 3A4 isoenzyme to the N-monodemethylated metabolite (RU 42 633); RU 42 698, which results from the loss of two methyl groups from position 11 beta; and RU 42 698, which results from terminal hydroxylation of the 17&#8211;propynyl chain.</p></td></tr><tr><th>Route of elimination</th><td>Fecal: 83%; Renal: 9%.</td></tr><tr><th>Half life</th><td>18 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Nearly all of the women who receive mifepristone will report adverse reactions, and many can be expected to report more than one such reaction. About 90% of patients report adverse reactions following administration of misoprostol on day three of the treatment procedure. Side effects include more heavy bleeding than a heavy menstrual period, abdominal pain, uterine cramping, nausea, vomiting, and diarrhea.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.7135</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6716</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.643</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8564</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8387</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8177</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7606</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.8334</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9106</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6293</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8931</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8994</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.796</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.6129</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.856
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.825
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9971
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7705 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9177
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6879
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Danco laboratories llc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Danco Labs LLC</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>200mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>300mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06695">Dabigatran etexilate</a></td><td>May lead to excessive post-abortion bleeding in patients on anticoagulant therapy. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB06699">Degarelix</a></td><td>Enhance QTc-prolonging effect </td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Mifepristone, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.</td></tr><tr><td><a href="/drugs/DB06663">Pasireotide</a></td><td>Avoid combination with mifepristone and other moderate to high risk QTc prolonging agents. The combinaton may enhance the QTc-prolonging effect of these drugs.</td></tr><tr><td><a href="/drugs/DB08895">Tofacitinib</a></td><td>Mifepristone, when used in combination with tofacitinib, may increase tofacitinib concentrations. It is recommended to adjust therapy by using a minimized dose of tofacitinib, and monitoring for increased tofacitinib concentrations and signs of toxicity, during and 2 weeks after discontinuation of mifepristone therapy.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>